Robert E. Bellet

1.7k total citations
35 papers, 1.4k citations indexed

About

Robert E. Bellet is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Robert E. Bellet has authored 35 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 9 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Robert E. Bellet's work include Cancer Treatment and Pharmacology (10 papers), Immunotherapy and Immune Responses (7 papers) and Cutaneous Melanoma Detection and Management (6 papers). Robert E. Bellet is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Immunotherapy and Immune Responses (7 papers) and Cutaneous Melanoma Detection and Management (6 papers). Robert E. Bellet collaborates with scholars based in United States, United Kingdom and Australia. Robert E. Bellet's co-authors include Michael J. Mastrangelo, David Berd, Vicente Valero, R S Walters, Giuseppe Fraschini, Aman U. Buzdar, Leticia Esparza, Gabriel N. Hortobágyi, Gustavo Fonseca and Frankie A. Holmes and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Robert E. Bellet

35 papers receiving 1.3k citations

Peers

Countries citing papers authored by Robert E. Bellet

Since Specialization

Citations

This map shows the geographic impact of Robert E. Bellet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Bellet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Bellet more than expected).

Fields of papers citing papers by Robert E. Bellet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Bellet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Bellet. The network helps show where Robert E. Bellet may publish in the future.

Co-authorship network of co-authors of Robert E. Bellet

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Bellet. A scholar is included among the top collaborators of Robert E. Bellet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Bellet. Robert E. Bellet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prevalence of neuro-musculoskeletal pain and dysfunction in open-heart surgical patients preoperatively and at 6 and 12 weeks postoperatively: a prospective longitudinal observation study 2017 ·PubMed ·Robert E. Bellet, (unknown), (unknown), Harry Bartlett	5
2	Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies 2008 ·Cancer Chemotherapy and Pharmacology ·Paula M. Fracasso, Joel Picus, (unknown), Sherry A. Goodner, (unknown), Feng Gao, Ramaswamy Govindan, Matthew J. Ellis, Benjamin Tan, Gerald P. Linette, (unknown), Helen S. Pentikis, (unknown), Merrill J. Egorin, Robert E. Bellet	40
3	A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy 2007 ·Journal of Clinical Oncology ·Robert E. Bellet, Hassan Ghazal, Marshall S. Flam, Anibal Drelichman, N. Gabrail, Donald Woytowitz, Danuta Z. Loesch, (unknown), Antoinette Mangione, Lowell Anthony, (unknown)	16
4	Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC) 2004 ·Journal of Clinical Oncology ·Robert E. Bellet, (unknown), Daniel P. Petrylak, Basil Kasimis, David Irwin, Manuel Modiano, Richard Mansour, R. Axelrod, Michail Doukas	3
5	A phase I study of docetaxel and 5-fluorouraciI in patients with advanced solid malignancies 1999 ·Annals of Oncology ·Thierry Petit, (unknown), Howard A. Burris, Peter M. Ravdin, Gladys Rodriguez, Lee Smith, N. W. Peacock, Leslie Smetzer, Robert E. Bellet, Daniel D. Von Hoff, Eric K. Rowinsky	13
6	Docetaxel in combination with fluorouracil: study design and preliminary results. 1997 ·PubMed ·Eric K. Rowinsky, Leia M. Smith, Gladys Rodriguez, (unknown), Ronald Drengler, D. Von Hoff, (unknown), (unknown), Howard A. Burris, P. Ravdin, Robert E. Bellet	1
7	Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. 1995 ·Journal of Clinical Oncology ·Vicente Valero, Frankie A. Holmes, R S Walters, Richard L. Theriault, Leticia Esparza, Giuseppe Fraschini, Gustavo Fonseca, Robert E. Bellet, Aman U. Buzdar, Gabriel N. Hortobágyi	325
8	Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. 1995 ·Journal of Clinical Oncology ·P. Ravdin, Howard A. Burris, Gary Cook, Peter D. Eisenberg, Maureen A. Kane, (unknown), (unknown), (unknown), Robert E. Bellet	275
9	The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma 1989 ·Cancer ·(unknown), Michael J. Mastrangelo, John D. Sprandio, Robert E. Bellet, David Berd	93
10	Frequency of Occult Residual Melanoma After Excision of a Clinically Positive Regional Lymph Node 1987 ·Annals of Surgery ·Michael P. Kane, Edward F. McClay, Robert E. Bellet	13
11	Preoperative Evaluation of the Oncology Patient 1987 ·Medical Clinics of North America ·Edward F. McClay, Robert E. Bellet	1
12	Primary Choroidal and Cutaneous Melanomas Occurring in a Patient with the B-K Mole Syndrome Phenotype 1980 ·American Journal of Ophthalmology ·Robert E. Bellet, Jerry A. Shields, David B. Soll, (unknown)	41
13	Evaluation of a “Nude” Mouse-Human Tumor Panel as a Predictive Secondary Screen for Cancer Chemotherapeutic Agents<xref ref-type="fn" rid="FN2">2</xref> 1979 ·JNCI Journal of the National Cancer Institute ·Robert E. Bellet, (unknown), Michael J. Mastrangelo, David Berd	43
14	A phase II evaluation of bacillus calmette‐guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma 1977 ·Medical and Pediatric Oncology ·(unknown), (unknown), (unknown), (unknown), Robert E. Bellet, Michael J. Mastrangelo	6
15	Multiple primary malignancies in patients with cutaneous melanoma 1977 ·Cancer ·Robert E. Bellet, (unknown), Michael J. Mastrangelo, Edward D. Lustbader	47
16	A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma 1977 ·Cancer ·(unknown), A. Bodurtha, Michael J. Mastrangelo, Robert E. Bellet	32
17	A Study of Antitumor (Phase II) and Immunosuppressive Effects of ICRF‐159 in Patients with Metastatic Melanoma 1976 ·The Journal of Clinical Pharmacology ·Robert E. Bellet, Robert B. Catalano, (unknown), David Berd, Jane Berkelhammer, Michael J. Mastrangelo	2
18	Estrogen-induced Hypernephroma 1974 ·The Journal of Urology ·Robert E. Bellet, (unknown)	12
19	Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study). 1973 ·PubMed ·Robert E. Bellet, Michael J. Mastrangelo, P F Engstrom, R P Custer	13
20	Phase I study of 5-azacytidine (NSC-102816) . 1972 ·PubMed ·Arthur J. Weiss, John E. Stambaugh, Michael J. Mastrangelo, (unknown), Robert E. Bellet	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact